234082-16-7

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Methyl 3-Chloro-4-piperazinobenzoate is used as a research compound for its potential therapeutic applications, particularly in the development of antipsychotic or neuroleptic agents. Its interactions with specific receptors in the brain make it a promising candidate for the treatment of various psychiatric disorders.
Used in the Synthesis of Pharmaceutical Compounds and Drug Intermediates:
In the pharmaceutical industry, Methyl 3-Chloro-4-piperazinobenzoate serves as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the creation of new drugs with potential therapeutic benefits, contributing to the advancement of medicinal chemistry.

Upstream product

• 234082-35-0 methyl 3-chloro-4-fluorobenzoate 
• 110-85-0 piperazine 

Downstream Products

• 234081-31-3 tert-butyl (2S)-benzenesulfonylamino-3-[3-chloro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoylamino]propionate 
• 234082-18-9 3-chloro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid 

Relevant academic research and scientific papers

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/ αIIbβ3 dual antagonistic activity

In order to generate novel compounds with integrin α vβ3-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective αIIbβ3 antagonists, replacement of piperazine with piperidine furnished a potent αvβ3/ αIIbβ3 dual antagonist. Structure-activity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists.

Phenylpiperazine derivatives as integrin αvβ3 antagonists

An objective of the present invention is to provide compounds having integrin αvβ3 antagonistic activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and therapeutic agents for treating integrin αvβ3-mediated diseases and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic ring containing two nitrogen atoms or the like; X and Z represent CH or a nitrogen atom; R4 and R5 represent alkyl, halogen or the like; Q represents >C=O, >CH2 or the like; R6 represents H, alkyl, aralkyl or the like; R7 represents H, alkynyl or the like; R8 represents H, substituted amino or the like; R9 represents H or alkyl; m is 0 to 5; n is 0 to 4; p is 2 or 3; and q is 0 or 1.